STAT+: Boundless Bio tests a cancer drug targeting once-mysterious DNA loops
SAN DIEGO — Peering through a microscope more than a half century ago, researchers made…
Category: STAT+
STAT+: Ketamine clinics’ bust serves as warning of business challenge facing psychedelic therapy
A chain of luxury ketamine clinics called Field Trip started churning through business strategies at…
STAT+: Biden drug czar to summon naloxone makers to White House to discuss pricing
WASHINGTON — The White House is summoning naloxone manufacturers for a roundtable focused on the…
STAT+: Envision Healthcare files for bankruptcy
Physician staffing firm Envision Healthcare officially filed for Chapter 11 bankruptcy on Monday, a move…
STAT+: U.S. Supreme Court declines to hear ‘skinny labeling’ case with implications for generic drug access
After months of anticipation, the U.S. Supreme Court declined to hear an appeal of a…
STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Hospital-insurer tussle in Arizona puts care denials front and center
UnitedHealthcare and Phoenix Children’s Hospital are embroiled in a bitter contract dispute that would lock…
STAT+: Masimo’s CEO on battling Apple for the health wearable market
It’s been a chaotic three years for Masimo CEO Joe Kiani. First came the pandemic,…
STAT+: FDA advisory panel narrowly recommends approval for Sarepta’s gene therapy for Duchenne
For an archived version of a live blog about Friday’s FDA advisory panel hearing, click…
STAT+: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations
And so, another working week will soon draw to a close. Not a moment too…
Tracking the FDA advisory panel on Sarepta’s gene therapy for Duchenne muscular dystrophy
The Food and Drug Administration is convening a meeting of outside experts on Friday to…
STAT+: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program
AbbVie has filed a lawsuit against a behind-the-scenes company that helps health plan sponsors take…
STAT+: Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at…
Key House Democrat demands NIH answer for pace of long Covid research
WASHINGTON — A powerful Democratic lawmaker is interrogating the National Institutes of Health over its…
STAT+: Scientists use ‘mini-brains’ to study microglia, the brain’s cleanup crew and key players in neurological disease
Home to billions of cells that form trillions of connections, the human brain isn’t just…
STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers
Thanks to changes in tax law six years ago, several of the largest pharmaceutical companies…
STAT+: Pharmalittle: FDA panel recommends first OTC birth control pill; Senate hearing on insulin costs satisfies no one
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: How the FDA’s pandemic flexibilities boosted mental health apps — and what happens now
In April 2020, the Food and Drug Administration announced a pandemic enforcement policy allowing mental…
.jpg)
STAT+: Telework helps FDA compete for scientists. What if it’s no longer an option?
WASHINGTON — The Food and Drug Administration needs to hire scores of in-demand scientists, and…
.jpg)
STAT+: Lawmakers press CMS to release new breakthrough device coverage rule
WASHINGTON — An array of lawmakers called for a simpler reimbursement pathway for breakthrough devices…
STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and…
STAT+: Google is training its generative AI to analyze medical images — and talk to doctors about them
Google’s generative AI system proved it can answer medical exam questions. But now the company…
STAT+: Pharmalittle: Gilead wins lawsuit against HHS over HIV pill patents; most Americans say abortion pill should remain on the market
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: FDA reviewers had string of concerns about Sarepta’s gene therapy for Duchenne, documents show
Reviewers at the Food and Drug Administration concluded that Sarepta Therapeutics did not show that…
STAT+: Brigham creates institute focused on immunology with record $100 million gift
Brigham and Women’s Hospital will launch a new institute focused on immunology and inflammation, thanks…
STAT+: In small study, weight loss drug boosts immune cells that help fight cancer
Drugs like Ozempic and Wegovy have become immensely popular for their ability to help people…
STAT+: What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history
In a fresh sign of quality-control problems in the Indian pharmaceutical industry, the U.S. Food…
STAT+: Gilead defeats federal government in closely watched battle over patents for HIV prevention pills
A U.S. court jury handed a major win to Gilead Sciences on Tuesday in a…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
STAT+: What to know about a pivotal FDA hearing on Sarepta’s gene therapy for Duchenne
On Friday, a committee of advisers to the Food and Drug Administration will meet to…
STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle
WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of…
STAT+: ‘Hard to catch up’: FDA commissioner on regulating new digital health tools
WASHINGTON — Digital health tools are developing faster than the Food and Drug Administration is able…
STAT+: EQRX abandons business plan around drug pricing, cuts jobs and programs
EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said…
STAT+: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease
When Herlda Senhouse looks back — way back — in time, she vividly remembers the smells…
STAT+: Pharmalittle: FDA panel to review over-the-counter birth control pill; Alzheimer’s drugs may lead to haves and have-nots
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Geisinger board member: Local consolidation influenced Kaiser-Geisinger deal
A long-running flurry of hospital and medical group acquisitions in Pennsylvania — especially among the…
STAT+: 4 ways the health care system should shift its thinking on AI, according to experts
This week, the “Godfather of AI” Geoffrey Hinton made news when he left Google and…
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval,…
STAT+: Pharmalittle: Pfizer and Valneva delay application for Lyme vaccine; Moderna adjusts price for Covid-19 shot
And so, another working week will soon draw to a close. Not a moment too…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: Gilead foresees more growth in its HIV drugs
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C….
STAT+: Senator pushes NIH for ‘formal’ review of Covid response
WASHINGTON — Republicans continued to press top health officials on the coronavirus response during a…
STAT+: Scientific research will be threatened unless NIH overhauls systems for tracking non-human primates, report warns
A worsening shortage of non-human primates and an inadequate government response threatens to undermine biomedical…
STAT+: A new list ranks large pharmaceutical companies by research and development
If you want a large pharmaceutical company to invent a new drug, your best bet…
STAT+: Option Care takes over Amedisys in ‘perplexing’ $3.6 billion home care deal
Option Care Health is buying Amedisys in an all-stock merger valued at $3.6 billion, creating…
STAT+: Pharmalittle: FDA OKs first RSV vaccine for older adults; Lilly Alzheimer’s data puts pressure on Medicare
Rise and shine, another busy day is on the way. We can tell by the…
STAT+: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced…
STAT+: CAR-T research is flourishing but is hampered by outdated precautions, experts say
Twenty years ago, CAR-T cell therapy was not quite “believed in,” said Michel Sadelain, director…
STAT+: Pharmalittle: Lilly’s Alzheimer’s drug slowed cognitive decline; most EU countries back plan to push production of key drugs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Immunogen ovarian cancer drug shown to extend patients’ lives
A drug approved in November as the first new treatment for advanced ovarian cancer in…